WM
MCID: WLD002
MIFTS: 68

Waldenstrom Macroglobulinemia (WM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Waldenstrom Macroglobulinemia

MalaCards integrated aliases for Waldenstrom Macroglobulinemia:

Name: Waldenstrom Macroglobulinemia 38 12 53 25 29 55 44 40 73
Lymphoplasmacytic Lymphoma 12 53 37 15
Macroglobulinemia of Waldenstrom 53 25
Waldenström Macroglobulinemia 25 59
Malignant Lymphoma - Lymphoplasmacytic 73
Waldenstrom's Macroglobulinaemia 53
Waldenstr�m's Macroglobulinemia 76
Waldenstrom's Macroglobulinemia 25
Waldenstrom's Syndrome 53
Wm 25

Characteristics:

Orphanet epidemiological data:

59
waldenström macroglobulinemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:



Summaries for Waldenstrom Macroglobulinemia

NIH Rare Diseases : 53 Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition. Treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues.

MalaCards based summary : Waldenstrom Macroglobulinemia, also known as lymphoplasmacytic lymphoma, is related to waldenstroem's macroglobulinemia and macroglobulinemia. An important gene associated with Waldenstrom Macroglobulinemia is MYD88 (MYD88, Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Akt Signaling. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are ataxia and respiratory insufficiency

Disease Ontology : 12 A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

Genetics Home Reference : 25 Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone marrow. This condition is classified as a lymphoplasmacytic lymphoma. The abnormal cells have characteristics of both white blood cells (lymphocytes) called B cells and of more mature cells derived from B cells known as plasma cells. These abnormal cells produce excess amounts of IgM, a type of protein known as an immunoglobulin; the overproduction of this large protein is how the condition got its name ("macroglobulinemia").

Wikipedia : 76 Waldenström''s macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, is a type of cancer... more...

Related Diseases for Waldenstrom Macroglobulinemia

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 1 Macroglobulinemia, Waldenstrom 2

Diseases related to Waldenstrom Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 32.8 BTK CXCR4 MAG MYD88
2 macroglobulinemia 32.5 BTK CD27 CD40LG CXCR4 ITGAE MYD88
3 myeloma, multiple 30.5 AKT1 CD27 CD40 CXCR4 TNFSF13B
4 cryoglobulinemia 30.4 CD27 CD40LG TNFSF13B
5 heavy chain disease 30.4 MYD88 PAX5
6 lymphocytic leukemia 30.1 BTK MYD88 PAX5 ZAP70
7 mantle cell lymphoma 30.1 AKT1 BTK CD40 PAX5
8 cryoglobulinemia, familial mixed 30.1 CD40LG IGHM
9 b-cell lymphomas 30.1 BTK CD40 PAX5 TNFSF13B
10 lymphoma, non-hodgkin, familial 30.0 CD27 CD40 CXCR4 PAX5 TNFSF13B
11 burkitt lymphoma 29.7 CD40 CD40LG MIR155 PAX5 TNFSF13B
12 leukemia, chronic lymphocytic 29.7 CD27 CD40 CD40LG CXCR4 IGHM PAX5
13 lymphoplasmacytic lymphoma without igm production 12.3
14 macroglobulinemia, waldenstrom 1 11.4
15 tibia, hypoplasia or aplasia of, with polydactyly 11.4
16 williams-beuren syndrome 11.4
17 weill-marchesani syndrome 11.3
18 microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma 11.0
19 weill-marchesani syndrome 2 11.0
20 weill-marchesani syndrome 3 11.0
21 lymphoma 10.4
22 light fixation seizure syndrome 10.3 CD40 CD40LG
23 immunoglobulin a deficiency 1 10.2 BTK CD40LG
24 cd40 ligand deficiency 10.2 CD40 CD40LG
25 immunodeficiency with hyper-igm, type 4 10.2 CD40 CD40LG TNFSF13B
26 hyperimmunoglobulin syndrome 10.2 CD40 CD40LG
27 monoclonal paraproteinemia 10.2 CD27 MYD88
28 immunodeficiency with hyper-igm, type 2 10.2 CD40 CD40LG TNFSF13B
29 primary central nervous system lymphoma 10.2 IGHM MYD88 PAX5
30 toxoplasmosis 10.2 CD40 CD40LG MYD88
31 sulfamethoxazole allergy 10.2 CD40 CD40LG
32 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.2 BTK CD40LG CXCR4
33 immunodeficiency with hyper-igm, type 1 10.2 BTK CD40 CD40LG
34 al amyloidosis 10.2
35 autoimmune lymphoproliferative syndrome, type v 10.2
36 agammaglobulinemia, non-bruton type 10.2 BTK IGHM
37 immune deficiency disease 10.2 BTK CD40 CD40LG
38 intraocular lymphoma 10.1 CXCR4 PAX5
39 immune system disease 10.1 BTK CD40 CD40LG TNFSF13B
40 agammaglobulinemia 1, autosomal recessive 10.1 BTK IGHM
41 agammaglobulinemia, x-linked 10.1 BTK CD40 CD40LG IGHM
42 leukemia 10.1
43 histiocytosis 10.1
44 autoimmune disease 10.1 CD40 CD40LG TNFSF13B ZAP70
45 transient hypogammaglobulinemia of infancy 10.1 BTK CD27 CD40 CD40LG
46 b cell deficiency 10.1 BTK CD27 CD40 CD40LG
47 epilepsy 10.0
48 plasma protein metabolism disease 10.0 BTK CXCR4 MAG MYD88
49 immunodeficiency with hyper-igm, type 3 10.0 CD40 CD40LG
50 stiff-person syndrome 10.0

Comorbidity relations with Waldenstrom Macroglobulinemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Neutropenia

Graphical network of the top 20 diseases related to Waldenstrom Macroglobulinemia:



Diseases related to Waldenstrom Macroglobulinemia

Symptoms & Phenotypes for Waldenstrom Macroglobulinemia

Human phenotypes related to Waldenstrom Macroglobulinemia:

59 32 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
2 respiratory insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002093
3 hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000365
4 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
5 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
6 malabsorption 59 32 occasional (7.5%) Occasional (29-5%) HP:0002024
7 reduced consciousness/confusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0004372
8 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
9 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
10 cranial nerve paralysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0006824
11 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
12 hypercoagulability 59 32 frequent (33%) Frequent (79-30%) HP:0100724
13 pallor 59 32 frequent (33%) Frequent (79-30%) HP:0000980
14 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
15 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
16 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
17 migraine 59 32 occasional (7.5%) Occasional (29-5%) HP:0002076
18 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
19 abnormality of the retinal vasculature 59 32 occasional (7.5%) Occasional (29-5%) HP:0008046
20 vertigo 59 32 frequent (33%) Frequent (79-30%) HP:0002321
21 purpura 59 32 occasional (7.5%) Occasional (29-5%) HP:0000979
22 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
23 recurrent infections 59 32 occasional (7.5%) Occasional (29-5%) HP:0002719
24 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
25 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
26 gingival bleeding 59 32 frequent (33%) Frequent (79-30%) HP:0000225
27 urticaria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001025
28 vasculitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002633
29 lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002665
30 stroke 59 32 occasional (7.5%) Occasional (29-5%) HP:0001297
31 periorbital edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0100539
32 proptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000520
33 abnormality of neutrophils 59 32 frequent (33%) Frequent (79-30%) HP:0001874
34 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
35 cutis marmorata 59 32 occasional (7.5%) Occasional (29-5%) HP:0000965
36 edema of the lower limbs 59 32 occasional (7.5%) Occasional (29-5%) HP:0010741
37 retinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0000573
38 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
39 pulmonary infiltrates 59 32 occasional (7.5%) Occasional (29-5%) HP:0002113
40 elevated erythrocyte sedimentation rate 59 32 occasional (7.5%) Occasional (29-5%) HP:0003565
41 normocytic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001897
42 leukemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001909
43 monoclonal immunoglobulin m proteinemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0005508
44 cryoglobulinemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100778
45 multifocal epileptiform discharges 59 32 occasional (7.5%) Occasional (29-5%) HP:0010841

GenomeRNAi Phenotypes related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 AKT1 CD40LG CXCR4 MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 AKT1 BTK CD27 CD40 CD40LG CXCR4

MGI Mouse Phenotypes related to Waldenstrom Macroglobulinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 AKT1 BTK CD27 CD40 CD40LG CXCR4
2 immune system MP:0005387 9.4 AKT1 BTK CD27 CD40 CD40LG CXCR4

Drugs & Therapeutics for Waldenstrom Macroglobulinemia

Drugs for Waldenstrom Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 379)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
5
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
7
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
8
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 147-94-4 6253
9
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
10
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
11
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
14
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
18
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
34
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Vitamin B9 Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 484)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab Completed NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
12 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
13 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
14 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
15 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
16 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
17 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
18 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
19 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
20 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
21 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
23 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
24 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
25 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
29 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
30 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
31 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
32 Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Recruiting NCT02626455 Phase 3 Copanlisib (BAY80-6946);Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Bendamustine;Prednisone
33 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
34 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
35 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
37 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
38 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
39 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
40 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
41 PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
42 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
43 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Unknown status NCT02566265 Phase 2
44 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Unknown status NCT00783367 Phase 2 lenalidomide-low dose dexamethasone plus rituximab;Lenalidomide + Rituximab
45 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
46 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
47 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
48 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
49 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
50 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid

Search NIH Clinical Center for Waldenstrom Macroglobulinemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Waldenstrom Macroglobulinemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Waldenstrom Macroglobulinemia:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Waldenstrom Macroglobulinemia:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: waldenstrom macroglobulinemia

Genetic Tests for Waldenstrom Macroglobulinemia

Genetic tests related to Waldenstrom Macroglobulinemia:

# Genetic test Affiliating Genes
1 Waldenstrom Macroglobulinemia 29 MYD88

Anatomical Context for Waldenstrom Macroglobulinemia

MalaCards organs/tissues related to Waldenstrom Macroglobulinemia:

41
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Spleen, Myeloid

Publications for Waldenstrom Macroglobulinemia

Articles related to Waldenstrom Macroglobulinemia:

(show top 50) (show all 213)
# Title Authors Year
1
Waldenstrom macroglobulinemia involving the superior rectus muscle. ( 29780960 )
2018
2
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. ( 28583038 )
2018
3
Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. ( 30315235 )
2018
4
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. ( 30402490 )
2018
5
Cutaneous macroglobulinosis as the initial presentation of Waldenström macroglobulinemia in a patient with a history of diffuse large B-cell lymphoma. ( 30073689 )
2018
6
High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia. ( 30190024 )
2018
7
CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression. ( 30408147 )
2018
8
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. ( 30426157 )
2018
9
Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. ( 30310784 )
2018
10
Prolymphocytic transformation of Lymphoplasmacytic lymphoma; an extremely unusual event. ( 30342054 )
2018
11
IgG lymphoplasmacytic lymphoma: a case report. ( 30238920 )
2018
12
A Case of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma With Lung Lesion. ( 30239460 )
2018
13
Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study. ( 30198549 )
2018
14
Beneficial Effect of Bendamustine in a Patient with Anti-MAG/SGPG Neuropathy and Bing-Neel Syndrome Associated with Waldenström Macroglobulinemia: A Case Report. ( 29983700 )
2018
15
Stiff-person Syndrome with Waldenström Macroglobulinemia. ( 29984750 )
2018
16
Ibrutinib in the management of Waldenstrom macroglobulinemia. ( 29996737 )
2018
17
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. ( 30044692 )
2018
18
Selecting Initial Therapy for Newly Diagnosed Waldenström Macroglobulinemia. ( 30052482 )
2018
19
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. ( 30104397 )
2018
20
Agranulocytosis Associated with Waldenström Macroglobulinemia. ( 30114687 )
2018
21
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. ( 30121949 )
2018
22
A Patient with Artifactually Low Serum High Density Lipoprotein Cholesterol Due to Waldenstrom Macroglobulinemia. ( 30181932 )
2018
23
Prediction of immunoglobulin M reduction via therapeutic dose of simple plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia. ( 30188580 )
2018
24
Genomic Landscape of Waldenström Macroglobulinemia. ( 30190014 )
2018
25
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond. ( 30190015 )
2018
26
The Bone Marrow Microenvironment in Waldenström Macroglobulinemia. ( 30190017 )
2018
27
Familial Waldenström Macroglobulinemia: Families Informing Populations. ( 30190018 )
2018
28
Initial Evaluation of the Patient with Waldenström Macroglobulinemia. ( 30190019 )
2018
29
Alkylating Agents in the Treatment of Waldenström Macroglobulinemia. ( 30190020 )
2018
30
Proteasome Inhibitors in Waldenström Macroglobulinemia. ( 30190021 )
2018
31
Monoclonal Antibodies for Waldenström Macroglobulinemia. ( 30190022 )
2018
32
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. ( 30190023 )
2018
33
Novel Approaches in Waldenström Macroglobulinemia. ( 30190025 )
2018
34
Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. ( 30190026 )
2018
35
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. ( 30192023 )
2018
36
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstrom Macroglobulinemia. ( 30206161 )
2018
37
Microarray-Based Gene Expression Analysis Identifies Potential Diagnostic and Prognostic Biomarkers for Waldenström Macroglobulinemia. ( 30227405 )
2018
38
Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia. ( 30241189 )
2018
39
Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab. ( 30246126 )
2018
40
Coexisting cutaneous macroglobulinosis and scleredema of Buschke in a patient with a Waldenström Macroglobulinemia. ( 30267590 )
2018
41
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. ( 30286096 )
2018
42
Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. ( 30305637 )
2018
43
Waldenström macroglobulinemia: 2018 update on diagnosis, risk stratification, and management. ( 30328142 )
2018
44
Thrombotic microangiopathy with intraglomerular IgM pseudothrombi in Waldenström macroglobulinemia and IgM monoclonal gammopathy. ( 30334170 )
2018
45
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. ( 30366921 )
2018
46
Kidney diseases associated with Waldenström macroglobulinemia. ( 30380110 )
2018
47
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. ( 30401751 )
2018
48
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia. ( 30455359 )
2018
49
Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies. ( 30485557 )
2018
50
SEROUS MACULAR DETACHMENT ASSOCIATED WITH WALDENSTROM MACROGLOBULINEMIA MANAGED WITH IBRUTINIB: A CASE REPORT AND NEW INSIGHTS INTO PATHOGENESIS. ( 30531550 )
2018

Variations for Waldenstrom Macroglobulinemia

Cosmic variations for Waldenstrom Macroglobulinemia:

9 (show all 31)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 2
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 2
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 2
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 2
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 2
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 2
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 2
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 2
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 2
10 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 2
11 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 2
12 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 2
13 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 2
14 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 2
15 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 2
16 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 2
17 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 2
18 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 2
19 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 2
20 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 2
21 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 2
22 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 2
23 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 2
24 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 2
25 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 2
26 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 2
27 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 2
28 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 2
29 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 2
30 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 2
31 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 2

Expression for Waldenstrom Macroglobulinemia

Search GEO for disease gene expression data for Waldenstrom Macroglobulinemia.

Pathways for Waldenstrom Macroglobulinemia

Pathways related to Waldenstrom Macroglobulinemia according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 AKT1 BTK CD27 CD40 CD40LG CXCR4
2
Show member pathways
13.18 AKT1 BTK CD27 CD40 CD40LG CXCR4
3
Show member pathways
12.76 CD40 CD40LG CXCR4 TNFSF13B ZAP70
4
Show member pathways
12.57 AKT1 BTK CD27 CD40 CD40LG CXCR4
5
Show member pathways
12.55 AKT1 CD40 CD40LG MYD88 TNFSF13B ZAP70
6
Show member pathways
12.54 AKT1 CD27 CD40 CD40LG CXCR4
7
Show member pathways
12.47 AKT1 BTK CD40 CD40LG IGHM ZAP70
8
Show member pathways
12.44 AKT1 BTK CD27 CD40 CD40LG MYD88
9 12.32 BTK CD40LG CXCR4 MYD88 PAX5 TNFSF13B
10
Show member pathways
12.29 AKT1 CD40 CD40LG ZAP70
11
Show member pathways
12.22 AKT1 BTK CD40 ZAP70
12 12.16 AKT1 BTK CD40 MYD88
13
Show member pathways
12.12 AKT1 BTK CXCR4 ITGAE MYD88
14
Show member pathways
12.1 AKT1 CD40 CD40LG MYD88
15
Show member pathways
11.64 CD40 CD40LG TNFSF13B
16 11.63 BTK MYD88 ZAP70
17
Show member pathways
11.59 AKT1 MAG MYD88
18 11.48 CD27 CD40 CD40LG
19 11.38 CD40 CD40LG MYD88
20 11.19 CD40 CD40LG ZAP70
21 11.19 BTK CD40 CD40LG ZAP70
22 11.13 AKT1 CD40 CD40LG
23 11.08 CD27 CD40 CD40LG CXCR4 PAX5
24 11.08 BTK CD40 CD40LG MYD88 TNFSF13B ZAP70
25 10.48 MAG MIR206

GO Terms for Waldenstrom Macroglobulinemia

Cellular components related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.77 AKT1 BTK CD27 CD40 CD40LG CXCR4
2 cell surface GO:0009986 9.55 CD27 CD40 CD40LG CXCR4 IGHM
3 external side of plasma membrane GO:0009897 9.1 CD27 CD40 CD40LG CXCR4 IGHM ITGAE

Biological processes related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 AKT1 CD40 CD40LG CXCR4 MYD88
2 immune system process GO:0002376 9.8 BTK CD40 IGHM MYD88 TNFSF13B ZAP70
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.67 BTK CD40 CD40LG MYD88
4 T cell costimulation GO:0031295 9.65 AKT1 CD40LG TNFSF13B
5 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.58 MIR155 MIR206 MIR494
6 positive regulation of T cell differentiation GO:0045582 9.54 CD27 ZAP70
7 immunoglobulin mediated immune response GO:0016064 9.52 CD27 MYD88
8 positive regulation of B cell differentiation GO:0045579 9.51 BTK CD27
9 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.49 AKT1 MYD88
10 regulation of immunoglobulin secretion GO:0051023 9.43 CD40 CD40LG
11 B cell activation GO:0042113 9.33 BTK CD40 ZAP70
12 immunoglobulin secretion GO:0048305 9.26 CD40LG TNFSF13B
13 cellular response to mechanical stimulus GO:0071260 9.26 AKT1 CD40 MAG MYD88
14 tumor necrosis factor-mediated signaling pathway GO:0033209 8.92 CD27 CD40 CD40LG TNFSF13B

Sources for Waldenstrom Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....